Oct 22 2009
BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced that revenue for the third quarter of 2009 continued to sustain the momentum experienced during the first two fiscal quarters of this year. A primary driver of third quarter revenue was the exceptional success of the company's expanded portfolio of specialty biotherapeutics.
"During Q3 2009, BDI Pharma celebrated completion of the first twelve (12) months of the most significant product portfolio expansion in the company's history," said William A. Shirey, III, Executive Vice President. "BDI Pharma is an organization founded on a customer-centric service model, and as such, since our inception in 1995, we have been repeatedly asked by our customers to provide additional specialty pharmaceuticals to complement the plasma protein therapy products that historically comprised the company's core business. Due to the initial positive response to these supplemental product lines, we revised our revenue projections upward after the first six months; however, sales uptake continued at such a pace that the final revenue numbers represented more than a fifty percent (50%) increase over those revised expectations."
Edward Steres, Vice President of Strategic Partnerships, stated, "During this same period, as BDI Pharma enhanced its product portfolio, we have established relationships with a number of innovative biotech and pharmaceutical manufacturers. These cutting-edge organizations now acknowledge BDI Pharma as an authorized distributor of record for their products, and as we forge ahead adding drugs to treat additional disease states, we will continue to cultivate relationships with the strategic addition of new limited distribution partnerships."